Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 2,828 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 2,828 shares of Castle Biosciences stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $35.04, for a total transaction of $99,093.12. Following the transaction, the insider directly owned 32,737 shares of the company’s stock, valued at $1,147,104.48. This represents a 7.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 1.5%

CSTL stock opened at $34.50 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.12 and a current ratio of 5.28. The company’s fifty day simple moving average is $34.33 and its 200 day simple moving average is $28.37. Castle Biosciences, Inc. has a 12-month low of $17.72 and a 12-month high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.22. Castle Biosciences had a negative return on equity of 4.89% and a negative net margin of 6.10%. The firm had revenue of $101.95 million during the quarter, compared to the consensus estimate of $92.76 million. As a group, research analysts predict that Castle Biosciences, Inc. will post -0.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds have recently bought and sold shares of the company. Assetmark Inc. grew its stake in shares of Castle Biosciences by 9.3% in the 1st quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock worth $142,000 after acquiring an additional 492 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Castle Biosciences by 255.3% in the third quarter. Allworth Financial LP now owns 938 shares of the company’s stock valued at $33,000 after purchasing an additional 674 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Castle Biosciences by 15.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,574 shares of the company’s stock valued at $194,000 after purchasing an additional 747 shares in the last quarter. NFSG Corp bought a new position in shares of Castle Biosciences during the third quarter valued at about $36,000. Finally, Global Retirement Partners LLC purchased a new position in Castle Biosciences during the second quarter worth about $26,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on CSTL. Robert W. Baird raised their target price on Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research note on Monday. Mizuho assumed coverage on shares of Castle Biosciences in a research note on Thursday, October 29th. They issued an “outperform” rating and a $60.00 price objective for the company. KeyCorp upped their price target on Castle Biosciences from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. BTIG Research upped their price objective on shares of Castle Biosciences from $44.00 to $52.00 and gave the stock a “buy” rating in a report on Monday. Finally, Wall Street Zen raised Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.